Please use this identifier to cite or link to this item:
Title: Polysomy of Chromosome 17: Its Clinicopathological Significance in Breast Cancer Female Patients in Kuwait
Authors: Farah M.Anwar Bakhsh 
Supervisor: Dr. Issam M.Francis
Keywords: Breast cancer;Her-2/neu Amplification;Polysomy 17;Immunohistoschemistry;FISH
Issue Date: 2012
Publisher:  Kuwait university - college of graduate studies
Abstract: Amplification of the HER-2/neu gene is one of the established prognostic markers that leads to protein overexpression in 25-30% of breast cancer cases. A subset of breast carcinoma showed polysomy of chromosome 17, which is encountered frequently during the assessment of HER-2/neu status. Unlike gene amplification, the role of polysomy 17 is uncertain. The hypothesis of this study is that polysomy 17, compared to HER-2/neu positive and HER2/neu negative, has a distinct impact on the clinicopathological features of breast cancer and it can be considered as a useful prognostic marker for breast tumor. We also hypothesized that polysomy 17 is an indirect mechanism that contributes to increased numbers of HER-2/neu gene resulting in protein overexpression in the absence of gene amplification. Therefore, 271 archival, formalin-fixed, paraffin-embedded blocks of breast cancer were collected. Expressions of ER, PR, Ki-67 and overexpression of HER-2/neu were studied using immunohistochemical method. The FISH assay was used to determine HER-2/neu gene amplification. The frequency of polysomy 17 was 13.6%. In relation to the anatomical site, stage, and histopathological type of the tumor, a statistically significant difference was observed between polysomy 17 and HER-2/neu negative. In addition, the ER status and PR status of polysomy 17 differed from those of HER-2/neu positive, and these differences were associated with hormone receptor positivity. Patients with polysomy 17 were also found to have the shortest OS (P = 0.001) and a trend toward shorter DFS. A highly significant association was observed between polysomy 17 and HER2/neu protein overexpression (P = 0.000) with a score of 2+ by IHC. These results suggest that polysomy 17 can be characterized as having different v clinicopathological features from either HER-2/neu positive or HER-2/neu negative tumors. Our results also showed that polysomy 17 has a significant biological influence on HER-2/neu protein overexpression and that it can be considered as a prognostic marker in breast cancer.
Appears in Programs:0570 Pathology (M.Sc.)

Files in This Item:
File Description SizeFormat 
Thieses.pdf5,68 MBAdobe PDFView/Open    Request a copy
Show full item record

Page view(s)

Last Week
Last month
checked on Jan 16, 2021


checked on Jan 16, 2021

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.